Ethyl methanesulphonate in a parenteral formulation of BMS-214662 mesylate, a selective farnesyltransferase inhibitor: Formation and rate of hydrolysis

Author： Nassar Munir N.   Cucolo Michael   Miller Scott A.  

Publisher： Informa Healthcare

ISSN： 1083-7450

Source： Pharmaceutical Development and Technology, Vol.14, Iss.6, 2009-12, pp. : 672-677

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Farnesyltransferase Inhibitor as Anticancer Agent

By  

Mini Reviews in Medicinal Chemistry, Vol. 9, Iss. 6, 2009-01 ,pp. : 638-652

Bentham Science Publishers

Access to resources Recommend Favorite

Modification of in vitro drug release rate from oily parenteral depots using a formulation approach

By Fredholt K.   Larsen D.H.   Larsen C.  

European Journal of Pharmaceutical Sciences, Vol. 11, Iss. 3, 2000-09 ,pp. : 231-237

Elsevier

Access to resources Recommend Favorite

Importance of using physiologically relevant volume of dissolution medium to correlate the oral exposure of formulations of BMS-480188 mesylate

By Gu C.-H.   Gandhi R.B.   Tay L.K.   Zhou S.   Raghavan K.  

International Journal of Pharmaceutics, Vol. 269, Iss. 1, 2004-01 ,pp. : 195-202

Elsevier

Access to resources Recommend Favorite

Impurities in a Lyophilized Formulation of BMS-204352: Identification and Role of Sanitizing Agents

By Nassar Munir   Nesarikar Vishwas   Khaselev Nona   Lozano Ruben  

Pharmaceutical Development and Technology, Vol. 11, Iss. 2, 2006-07 ,pp. : 207-211

Informa Healthcare

Access to resources Recommend Favorite

Development of an Omeprazole Parenteral Formulation with Hydroxypropyl-β-Cyclodextrin

By Holvoet Chantal   Heyden Yvan Vander   Plaizier-Vercammen Jacqueline  

Pharmaceutical Development and Technology, Vol. 12, Iss. 3, 2007-05 ,pp. : 327-336

Informa Healthcare

Access to resources Recommend Favorite